Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II open-label study evaluating the preliminary efficacy and safety of
bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory
Prostate Cancer.